U.S. FDA extends review period for expanded use of Abbvie's arthritis drug
FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange
Read more
FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange
Read more